期刊
BIOMOLECULES
卷 12, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/biom12101450
关键词
STAT3; pancreatic cancer; drug therapy; molecular targeted therapy
资金
- National Natural Science Foundation of China [82260555]
- Gansu Traditional Chinese Medicine Research Project [GZKP-2020-28]
- Natural Science Foundation of Gansu Province [2020-0405-JCC-1871]
- Lanzhou City Chengguan District Science and Technology Plan Project [2020-2-11-4]
This review discusses the relationship between STAT3 and pancreatic cancer, as well as the latest research on the use of STAT3 inhibitors in pancreatic cancer, aiming to provide insights and ideas for a new generation of chemotherapeutic modalities for pancreatic cancer.
The signal transducer and activator of transcription (STAT) is a family of intracellular cytoplasmic transcription factors involved in many biological functions in mammalian signal transduction. Among them, STAT3 is involved in cell proliferation, differentiation, apoptosis, and inflammatory responses. Despite the advances in the treatment of pancreatic cancer in the past decade, the prognosis for patients with pancreatic cancer remains poor. STAT3 has been shown to play a pro-cancer role in a variety of cancers, and inhibitors of STAT3 are used in pre-clinical and clinical studies. We reviewed the relationship between STAT3 and pancreatic cancer and the latest results on the use of STAT3 inhibitors in pancreatic cancer, with the aim of providing insights and ideas around STAT3 inhibitors for a new generation of chemotherapeutic modalities for pancreatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据